Perrigo Company plc

NYSE:PRGO

Drug Manufacturers - Specialty & Generic

Healthcare
$16.94 -1.97%

-$0.20 today

Market cap
$2.35B
Beta
0.52
P/E (TTM)
-0.8
EPS (TTM)
-$13.10
Dividend yield
11.65%
52W Low $9.23High $28.44

Volume 2.57M

Average 2.96M

PRGO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Perrigo Company plcNYSE: PRGO

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $229.5M fell 16.0% year over year, ahead of the -68.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 76.9% from the prior quarter. Over 3 fiscal years it compounded at -24.2% a year.

Context

  • Selling, general & admin amounted to 12.4% of revenue in FY2025, down 13.1 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $951.86M (+80.8%) for the fiscal year ending Dec 2026, a step up from the -52.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$229.5M+76.9% QoQ
Last fiscal yearDec 2025
$526.5M-52.7% YoY
LTMJun 2026
$331.4M-68.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.0%+6.0%+22.0 pp
1 year-52.7%+80.8%+133.5 pp
3-year CAGR-24.2%+19.7%+44.0 pp
5-year CAGR+13.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
526.5M USD
Year-over-year change
-52.7%
4-year CAGR
-17.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PRGO compares with its peers on the latest reported figures

  • PRGO's LTM Jun 2026 selling, general & admin of $331.4M is the 7th highest of the 10 companies compared; the peer median is $493.34M.
  • Its year-over-year change of -68.8% is the lowest of 10, against a peer median of +10.0%.
  • Selling, general & admin amounts to 8.0% of revenue for PRGO, versus a peer median of 62.7%.
PRGO Competitors Peer median
Selling, General & Admin for PRGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$3.45B +0.5%+10.7%31.7%
LIVNLivaNova PLCLTM Sep 2026$599.94M +10.0%+5.4%39.8%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$585.83M +60.2%+111.8%85.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$560.88M +68.6%+8.8%67.5%
ATECAlphatec Holdings, Inc.LTM Mar 2026$493.34M +6.4%+18.4%62.7%
SGRYSurgery Partners, Inc.LTM Sep 2026$344.3M -20.3%+72.3%10.2%
PRGOPerrigo Company plcLTM Jun 2026$331.4M -68.8%-24.2%8.0%
SRRKScholar Rock Holding CorporationLTM Sep 2026$198.39M +32.1%+60.5%34804.4%
HTFLHeartflow, Inc. Common StockLTM Sep 2026$170.82M +35.3%—71.6%
HCMHUTCHMED (China) LimitedLTM Jun 2025$96.73M -21.2%-8.8%16.1%
Peer median (excluding PRGO) $493.34M+10.0%+14.6%62.7%

Competitors are the stored peer set for PRGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.14B4.45B4.66B4.37B4.25B
Cost of Revenue2.72B3B2.98B2.83B2.76B
Gross Profit1.42B1.46B1.68B1.54B1.49B
Gross Margin34.2%32.7%36.1%35.3%35.1%
Research & Development122M123.1M122.5M112.2M95.4M
Selling, General & Admin1.11B1.21B1.27B1.11B526.5M
Operating Expenses1.01B1.38B1.53B1.43B1.15B
Depreciation & Amortization312.2M338.6M359.5M325.9M337.5M
EBITDA695.9M355.5M525M433M(797.9M)
EBITDA Margin16.8%8.0%11.3%9.9%-18.8%
Operating Income410.4M78.9M151.9M112.9M343.3M
Operating Margin9.9%1.8%3.3%2.6%8.1%
Interest Income00000
Interest Expense125M156M173.8M187.8M162.5M
Other Income / Expenses(151.7M)(218M)(160.2M)(193.6M)(1.64B)
Income Before Tax258.7M(139.1M)(8.3M)(80.7M)(1.3B)
Pre-Tax Margin6.3%-3.1%-0.2%-1.8%-30.5%
Income Tax Expense389.6M(8.2M)(3.9M)80M104.4M
Net Income(68.9M)(140.6M)(12.7M)(171.8M)(1.43B)
Net Margin-1.7%-3.2%-0.3%-3.9%-33.5%
EPS (Basic)(0.98)(0.97)(0.09)(1.25)(10.29)
EPS (Diluted)(0.98)(0.97)(0.09)(1.25)(10.29)
Weighted Avg Shares133.6M134.5M135.3M137.4M138.5M
Weighted Avg Shares (Diluted)133.6M134.5M135.3M137.4M138.5M

Perrigo Company plc

NYSE:PRGO

Intrinsic Alpha fair value

Locked

Current Price

$16.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.